Skip to main content

Site notifications

DAYVIGO (Eisai Australia Pty Ltd)

Product name
DAYVIGO
Date registered
Evaluation commenced
Decision date
Approval time
224 (255 working days)
Active ingredients
lemborexant
Registration type
NCE/NBE
Indication

DAYVIGO (film coated tablet) is indicated for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance in accordance with latest DSM criteria.

Help us improve the Therapeutic Goods Administration site